electroCore, Inc. (ECOR) Q1 2025 Earnings Call Transcript
Revenue $6.7 million, a 23% increase from $5.4 million in Q1 2024, driven by increased sales of prescription gammaCore devices and non-prescription Truvaga products.
Gross Profit $5.7 million, up from $4.6 million in Q1 2024, primarily due to the increase in net sales.
Gross Margin 85%, compared to 84% in Q1 2024, reflecting improved sales performance.
Prescription gammaCore VA Revenue $4.7 million, a 22% increase from $3.9 million in Q1 2024, attributed to increased purchases by VA facilities.
Truvaga Net Sales $1.1 million, a 187% increase from Q1 2024, driven by effective advertising and increased consumer awareness.
U.S. Prescription Channel Revenue $289,000, down 33% from Q1 2024, as cash pay customers migrated to the Truvaga brand.
Revenue from Outside the U.S. (OUS) $513,000, up from $449,000 in Q1 2024, primarily from prescription gammaCore sales in the UK.
Total Operating Expenses $9.5 million, compared to $8.4 million in Q1 2024, due to increased investment in sales and marketing and year-end reporting expenses.
GAAP Net Loss $3.9 million, compared to $3.5 million in Q1 2024, attributed to changes in below-the-line items and increased transaction fees.
Net Loss per Share $0.47, compared to $0.53 in Q1 2024, indicating a slight improvement in loss per share.
Adjusted EBITDA Net Loss $3.1 million, flat compared to $3.2 million in Q1 2024, showing stability in operational performance.
Cash and Cash Equivalents Approximately $8 million as of March 31, 2025, down from $12.2 million as of December 31, 2024, due to higher cash disbursements.
Net Cash Used in Operating Activities $4.4 million, compared to $1.3 million in Q4 2024, due to seasonal expenses and changes in working capital.
Trade with 70% Backtested Accuracy
Analyst Views on ECOR
About ECOR
About the author
electroCore CEO Announces Retirement and New Leadership Appointments
- Leadership Transition: electroCore CEO Daniel Goldberger announced his retirement effective April 1, 2026, marking a pivotal shift in the company's financial and commercial strategy, with CFO Joshua Lev appointed as Interim President to ensure stability during the leadership transition.
- Strong Financial Performance: The company reported fourth-quarter 2025 revenue of $9.2 million, a 31% year-over-year increase, with full-year revenue reaching $32 million, a 27% growth over 2024, indicating sustained market demand for non-invasive pain therapeutics.
- Optimistic Outlook: Management expects revenue for 2026 to continue growing at approximately 30%, although detailed guidance is not provided due to the leadership transition; however, third-quarter activities suggest ongoing product acceptance in the market.
- Product Expansion Plans: The company plans to launch Quell Relief for lower extremity pain in 2026 and is developing next-generation mobile applications for both Truvaga and Quell, aiming to further expand the applications of its non-invasive neuromodulation platform.
electroCore (ECOR) Q4 2025 Earnings Transcript
ElectroCore Releases 2026 Financial Outlook with Revenue Growth Guidance
- Earnings Beat: ElectroCore reported a FY GAAP EPS of -$1.65, beating expectations by $0.07, indicating an improvement in financial performance despite still being in a loss position.
- Significant Revenue Growth: The company's FY 2023 revenue reached $32.02 million, reflecting a 27.2% year-over-year increase and surpassing market expectations by $70,000, demonstrating sustained demand for its neuromodulation platform.
- Positive 2026 Outlook: ElectroCore anticipates approximately 30% revenue growth in 2026 compared to 2025, showcasing confidence in future market opportunities that may attract more investor interest.
- Market Assessment Improvement: According to Seeking Alpha's Quant Rating, ElectroCore's revenue forecast for 2025 is between $31.8 million and $32 million, further validating market recognition of its business evolution and strategic priorities.
ElectroCore Set to Announce FY Earnings Results
- Earnings Announcement: ElectroCore (ECOR) is scheduled to release its FY earnings report on March 19th after market close, with investors keenly awaiting the results to gauge the company's future growth prospects.
- Earnings Expectations: The consensus EPS estimate stands at -$0.39, reflecting a significant year-over-year improvement of 75.5%, indicating the company's efforts to enhance profitability.
- Revenue Projections: The consensus revenue estimate is $31.95 million, representing a 26.9% year-over-year increase, showcasing ElectroCore's growth potential in its neuromodulation platform business.
- Historical Performance Review: Over the past year, ElectroCore has not beaten EPS estimates at all, while it has exceeded revenue estimates 25% of the time, suggesting a relative stability in revenue growth despite challenges in profitability.
electroCore (ECOR) Projects 2025 Revenue Between $31.8M and $32M
- Revenue Guidance: electroCore anticipates 2025 revenue between $31.8M and $32M, slightly below the consensus of $31.81M, indicating a cautious outlook on future growth.
- Q4 Growth Projection: The company expects Q4 2025 revenue to be between $9M and $9.2M, representing approximately 30% growth over Q4 2024, suggesting strengthening competitive positioning in the market.
- Cash Position: By the end of 2025, electroCore expects to have approximately $11.6M in cash, down from about $13.2M as of September 30, 2025, reflecting pressure from expansion and investment expenditures.
- Market Reaction: ECOR shares fell 0.62% in premarket trading to $7.0957, indicating investor caution regarding the revenue outlook.
ElectroCore Increases 2025 Revenue Forecast to $32.5M Amid Enhanced Investments and Strategic Growth
Management Strategy: Dr. Thomas Errico highlighted a strategic shift towards growth through targeted investments, acquisitions, and partnerships, focusing on expanding product offerings and enhancing shareholder value while deferring profitability.
Financial Performance: The company reported a record revenue of $8.7 million for Q3 2025, a 33% increase year-over-year, with strong gross margins of 86%, driven by prescription device sales and growth in the VA hospital system.
Outlook and Guidance: CEO Daniel Goldberger raised the full-year revenue guidance to $31.5 million to $32.5 million, projecting a cash balance of approximately $10.5 million by year-end and aiming for positive adjusted EBITDA in the second half of 2026.
Risks and Challenges: Management acknowledged ongoing litigation and the impact of macroeconomic factors on revenue, emphasizing that continued investments in sales and R&D may delay near-term profitability but are essential for long-term growth.
electroCore CEO Announces Retirement and New Leadership Appointments
- Leadership Transition: electroCore CEO Daniel Goldberger announced his retirement effective April 1, 2026, marking a pivotal shift in the company's financial and commercial strategy, with CFO Joshua Lev appointed as Interim President to ensure stability during the leadership transition.
- Strong Financial Performance: The company reported fourth-quarter 2025 revenue of $9.2 million, a 31% year-over-year increase, with full-year revenue reaching $32 million, a 27% growth over 2024, indicating sustained market demand for non-invasive pain therapeutics.
- Optimistic Outlook: Management expects revenue for 2026 to continue growing at approximately 30%, although detailed guidance is not provided due to the leadership transition; however, third-quarter activities suggest ongoing product acceptance in the market.
- Product Expansion Plans: The company plans to launch Quell Relief for lower extremity pain in 2026 and is developing next-generation mobile applications for both Truvaga and Quell, aiming to further expand the applications of its non-invasive neuromodulation platform.
electroCore (ECOR) Q4 2025 Earnings Transcript
ElectroCore Releases 2026 Financial Outlook with Revenue Growth Guidance
- Earnings Beat: ElectroCore reported a FY GAAP EPS of -$1.65, beating expectations by $0.07, indicating an improvement in financial performance despite still being in a loss position.
- Significant Revenue Growth: The company's FY 2023 revenue reached $32.02 million, reflecting a 27.2% year-over-year increase and surpassing market expectations by $70,000, demonstrating sustained demand for its neuromodulation platform.
- Positive 2026 Outlook: ElectroCore anticipates approximately 30% revenue growth in 2026 compared to 2025, showcasing confidence in future market opportunities that may attract more investor interest.
- Market Assessment Improvement: According to Seeking Alpha's Quant Rating, ElectroCore's revenue forecast for 2025 is between $31.8 million and $32 million, further validating market recognition of its business evolution and strategic priorities.
ElectroCore Set to Announce FY Earnings Results
- Earnings Announcement: ElectroCore (ECOR) is scheduled to release its FY earnings report on March 19th after market close, with investors keenly awaiting the results to gauge the company's future growth prospects.
- Earnings Expectations: The consensus EPS estimate stands at -$0.39, reflecting a significant year-over-year improvement of 75.5%, indicating the company's efforts to enhance profitability.
- Revenue Projections: The consensus revenue estimate is $31.95 million, representing a 26.9% year-over-year increase, showcasing ElectroCore's growth potential in its neuromodulation platform business.
- Historical Performance Review: Over the past year, ElectroCore has not beaten EPS estimates at all, while it has exceeded revenue estimates 25% of the time, suggesting a relative stability in revenue growth despite challenges in profitability.
electroCore (ECOR) Projects 2025 Revenue Between $31.8M and $32M
- Revenue Guidance: electroCore anticipates 2025 revenue between $31.8M and $32M, slightly below the consensus of $31.81M, indicating a cautious outlook on future growth.
- Q4 Growth Projection: The company expects Q4 2025 revenue to be between $9M and $9.2M, representing approximately 30% growth over Q4 2024, suggesting strengthening competitive positioning in the market.
- Cash Position: By the end of 2025, electroCore expects to have approximately $11.6M in cash, down from about $13.2M as of September 30, 2025, reflecting pressure from expansion and investment expenditures.
- Market Reaction: ECOR shares fell 0.62% in premarket trading to $7.0957, indicating investor caution regarding the revenue outlook.
ElectroCore Increases 2025 Revenue Forecast to $32.5M Amid Enhanced Investments and Strategic Growth
Management Strategy: Dr. Thomas Errico highlighted a strategic shift towards growth through targeted investments, acquisitions, and partnerships, focusing on expanding product offerings and enhancing shareholder value while deferring profitability.
Financial Performance: The company reported a record revenue of $8.7 million for Q3 2025, a 33% increase year-over-year, with strong gross margins of 86%, driven by prescription device sales and growth in the VA hospital system.
Outlook and Guidance: CEO Daniel Goldberger raised the full-year revenue guidance to $31.5 million to $32.5 million, projecting a cash balance of approximately $10.5 million by year-end and aiming for positive adjusted EBITDA in the second half of 2026.
Risks and Challenges: Management acknowledged ongoing litigation and the impact of macroeconomic factors on revenue, emphasizing that continued investments in sales and R&D may delay near-term profitability but are essential for long-term growth.
